The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3131)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05071716
Recruitment Status : Active, not recruiting
First Posted : October 8, 2021
Last Update Posted : March 22, 2024
Information provided by (Responsible Party):
Bausch Health Americas, Inc.

Brief Summary:
Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

Condition or disease Intervention/treatment Phase
Hepatic Encephalopathy Drug: Rifaximin SSD Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 524 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
Actual Study Start Date : April 7, 2022
Estimated Primary Completion Date : September 2025
Estimated Study Completion Date : September 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Rifaximin SSD-40mg IR Drug: Rifaximin SSD
Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily

Placebo Comparator: Placebo Drug: Placebo
Placebo Twice Daily

Primary Outcome Measures :
  1. Time to first event of overt hepatic encephalopathy requiring hospitalization [ Time Frame: 72 weeks ]

Secondary Outcome Measures :
  1. Time to first Conn score ≥ 2 [ Time Frame: 72 weeks ]
  2. Time to all-cause hospitalization [ Time Frame: 72 weeks ]
  3. Time to first event of OHE that requires hospitalization, or all-cause death [ Time Frame: 72 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Diagnosis of liver cirrhosis with medically controlled ascites (>30 days) not requiring therapeutic paracentesis (could have had paracentesis in the past).
  • Conn (West Haven Criteria) score of < 2.
  • Mini-Mental State Examination (MMSE) score > 24 at screening.
  • ≥ 18 and ≤ 85 years of age.

Key Exclusion Criteria:

  • Active COVID-19 that is unresolved
  • History of SBP
  • History of EVB or AKI-HRS within 6 months
  • History of OHE episode (Conn score ≥ 2)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05071716

Show Show 150 study locations
Sponsors and Collaborators
Bausch Health Americas, Inc.
Layout table for investigator information
Study Director: Michael Mader Bausch Health
Layout table for additonal information
Responsible Party: Bausch Health Americas, Inc. Identifier: NCT05071716    
Other Study ID Numbers: RNLC3131
First Posted: October 8, 2021    Key Record Dates
Last Update Posted: March 22, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatic Encephalopathy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases
Brain Diseases, Metabolic
Metabolic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Gastrointestinal Agents